Background
Methods
Search strategy
Selection strategy
Data extraction and risk of bias
Results
Characteristics of the studies
Study | Features study | Features participants | Features intervention | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Coun-try | Follow-up (months) | Design | Disorder | Sample size | Completed study | Age | Sex (% male) | Intervention | Number of sessions per week | Treatment duration (weeks) | ||||||
I | C | I | C | I | C | I | C | I | C | |||||||
Schoenwald et al., 1996 [32] | USA | 6 AT | RCT | SUD | 59 | 59 | NS | 16 | 79 | MST | CAU | 2–3b
| 18–19 | |||
French et al., 2003 [22] | USA | 12a
| RCT | SUD | Trial 1: | |||||||||||
102 | 564 | 16 | 81 | MET/CBT5 | 0–1 | 6–7 | ||||||||||
96 | 16 | 86 | MET/CBT12 | 0–1 | 12–14 | |||||||||||
102 | 16 | 84 | FSN | 1–2 | 12–14 | |||||||||||
Trial 2: | ||||||||||||||||
100 | 16 | 79 | MET/CBT5 | 0–1 | 6–7 | |||||||||||
100 | 16 | 80 | ACRA | 1–2 | 12–14 | |||||||||||
100 | 16 | 85 | MDFT | 1–2 | 12–14 | |||||||||||
Sheidow et al., 2004 [23] | USA | 12 AT | RCT | PC | 115 | NS | 13 | 67 | MST | CAU | NS | 16 | ||||
Dennis et al., 2004 [29] | USA | 12 | RCT | SUD | 564 | Trial 1: | ||||||||||
102 | 16 | MET/CBT | 0–1 | 6–7 | ||||||||||||
96 | 16 | 5 | 0–1 | 12–14 | ||||||||||||
102 | 16 | MET/CBT | 1–2 | 12–14 | ||||||||||||
12 | ||||||||||||||||
100 | 16 | FSN | 0–1 | 6–7 | ||||||||||||
100 | 16 | Trial 2: | 1–2 | 12–14 | ||||||||||||
100 | 16 | MET/CBT | 1–2 | 12–14 | ||||||||||||
5 | ||||||||||||||||
ACRA | ||||||||||||||||
MDFT | ||||||||||||||||
McCollister et al., 2009 [24] | USA | 12 | RCT | SUD | 38 | 42 | NS | 1 | 1 | 84 | 81 | DC | FC | NS1
| NS1
| |
38 | 5 | 5 | 84 | DC + MST | ||||||||||||
43 | 15 | 4 | DC + MST + CM | |||||||||||||
15 | ||||||||||||||||
French et al., 2008 [25] | MEX | 7 | RCT | SUD | 30 | 30 | 114 | 16 | 1 | 80 | 83 | FFT | group | NS1
| NS1
| |
29 | 16 | 6 | 76 | Joint | ||||||||||||
31 | 16 | 84 | CBT | |||||||||||||
Olsson, 2010 [26] | SW | 24 | RCT | CD | 79 | 77 | NS | 15 | 61 | MST | CAU | NS | 12–20 | |||
Sheidow et al., 2012 [27] | USA | 12 | RCT | SUD | 38 | 4 | 29 | 33 | 15 | 83 | DC | FC | NS1
| NS1
| ||
38 | 2 | 29 | DC + MST | |||||||||||||
43 | 37 | DC + MST + CM | ||||||||||||||
Cary et al., 2013 [28] | ENG | 30 | RCT | DEL | 56 | 52 | 46 | 45 | 15 | 15 | 83 | 82 | MST+ | CAU | 3 | 20 |
CAU | ||||||||||||||||
Dopp et al. (2014) [30] | USA | 300 | RCT | DEL | 92 | 84 | 70 | 56 | 15 | 69 | MST | CAU | 3–4 | 21 | ||
Borduin et al. (2015) [31] | USA | 107 | RCT | DEL | 24 | 24 | 24 | 22 | 14 | 96 | MST-PSB | CAU | 3 | 31 |
FSN | Cognitive behavioral sessions and motivation treatment in combination with a family component. |
MET/CBT5 | Motivational component and a cognitive behavioral component, to enhance motivation to change drug abuse and to grow the skills to maintain and regulate abstinence |
MET/CBT12 | MET/CBT5+ 7 sessions of CBT are added to the therapy. |
FC | Family court treatment with community services/Appearance court 2 times a year/ outpatient alcohol and drug abuse service from the local center of the state’s substance abuse commission |
DC | Drug court treatment with community services/Appearance court 1 time a week/ outpatient alcohol and drug abuse service from the local center of the state’s substance abuse commission and monitoring drug abuse |
CM | Frequent in home screens for drug use, voucher system contingent on clean screens, and drug refusal training. |
ACRA | Identifying reinforces that are incompatible with the drug use and to strengthen those |
CAU | Sheidow et al. [23]: admission to a psychiatric unit and aftercare |
Schoenwald et al. [32]: outpatient substance abuse services | |
Olsson et al. [26]: Not described | |
Cary at al. [28]: Youth Offending Team (YOT) | |
Dopp et al. [30]; Individual Therapy (IT) | |
Borduin et al. [31]: Cognitive behavioral group therapy and individual services (from local juvenile court) |
Outcomes of the studies
Studies considering costs and effects of substance abuse | ||||||
---|---|---|---|---|---|---|
Dennis (2004) [29] | Costs intervention and comparators (per episode of care per patient) (MET/CBT 5, MET/CBT 12, FSN, ACRA, MDFT) In trial 1 MET/CBT 5,MET/CBT 12 and FSN were compared. In trial 2 MET/CBT 5, ACRA and MDFT were compared. Costs were collected with a program (DATCAP) which yields estimates such as the total annual opportunity cost of treatment and the labor cost per client. | Difference cost | ||||
The difference in costs were not showed in this study. However, it was showed that the differences were significant. | ||||||
MET/CBT 5 (trial 1): € 1,226 MET/CBT 12 (trial 1): € 1,305 FSN (trial 1): € 3,576 | MET/CBT 5 (trial 2): €1,716 ACRA (trial 2): € 1,551 MDFT (trial 2): € 2,205 | |||||
Effects intervention and comparators (per patient) (MET/CBT 5, MET/CBT 12, FSN, ACRA, MDFT) | Difference effects | |||||
Met CBT 5 (trial 1) Days of abstinence: 269 Recovery*: 28 % Met CBT 12 (trial 1) Days of abstinence: 256 Recovery: 17 % MET FSN (trial 1) Days of abstinence: 260 Recovery: 22 % *Recovery is defined as having no use or abuse dependence problems and living in the community | Met CBT 5 (trial 2) Days of abstinence: 251 Recovery: 23 % ACRA (trial 2) Days of abstinence: 265 Recovery: 34 % MDFT (trial 2) Days of abstinence: 257 Recovery: 19 % | The difference in effects were not showed in this study However it was showed that the difference was not significant. | ||||
Results | Cost per day of abstinence: Met CBT5 (trial 1): € 541 Met CBT 12: € 677 Met FSN: € 1,667 Costs per person in recovery Met CBT5 (trial 1): € 4,360 Met CBT 12: € 41,172 Met FSN: € 16,651 | Cost per days of abstinence: MET/CBT5 (trial 2): € 991 ACRA: € 729 MDFT: € 1,143 Costs per person in recovery MET/CBT5 (trial 2): € 7,337 ACRA: € 4,913 MDFT: € 12,970 | ||||
French (2008) [25] | Costs intervention per patient (FFT, Joint and CBT) FFT: Treatment costs: € 1,817 Joint: treatment costs: € 2,847 CBT: Treatment costs: € 1.439 | Costs comparator per patient (Group) Group: Treatment costs: € 990 | Difference costs | |||
The difference in costs were not showed in this study | ||||||
Effects intervention per patient (FFT, Joint and CBT) FFT: % days marijuana use 4 months: 25.3 %of days marijuana use 7 months:39.8 YSR delinquency score 4 months: 8.2 YSR delinquency score 7 months:9.2 Joint % of days of marijuana use 4 months: 38.1 marijuana use 7 months:35.4 YSR delinquency score 4 months: 9.1 YSR delinquency score 7 months:8.5 CBT % of days marijuana use 4 months: 50.6 % of days marijuana use 7 months:51.8 YSR delinquency score 4 months: 10.2 YSR delinquency score 7 months:10.4 | Effects comparator per patient (Group) Group % of days of marijuana use 4 months: 54.8 marijuana use 7 months: 40.7 YSR delinquency score 4 months: 9.5 lYSR delinuency score 7 months: 9.4 | Difference effects with regression model: | ||||
FFT versus group: % days marijuana use after 4 months: −20.11* % days marijuana use after 7 months: 4.87 YSR delinquency score 4 months: −0.60 YSR delinquency score 7 months: 0.15 CBT versus group % days marijuana use after 4 months: 4.76 % days marijuana use after 7 months: 18.27 YSR delinquency score 4 months: 0.38 YSR delinquency score 7 months: 0.42 Joint versus group % days marijuana use after 4 months: −14.86 % days marijuana use after 7 months “-2.00 YSR delinquency score 4 months: −0.50 YSR delinquency score 7 months: −1.50 | Joint versus group Delinquency score after 4 months: −0.50 Delinquency score after 7 months: −1.50 | |||||
Results | Group therapy was most cost-effective, none of the other therapies were significantly different in effect compared to group therapy. So the intervention with the lowest costs was considered to be most cost-effective. | |||||
Sheidow (2012) [27] | Costs Intervention (DC, DC + MST, DC + MST + CM) Treatment costs DC: € 9,083 Treatment costs DC + MST: € 12,369 Treatment costs DC + MST + CM: € 12,859 | Costs comparator (FC) Treatment costs FC: € 3,679 | Difference costs: | |||
The difference in costs were not shown in this study | ||||||
Effects intervention (DC, DC + MST, DC + MST + CM) DC Marijuana use (days): −16.65 Polydrug use (days): 1.41 Alcohol use (days): 0.49 Heavy alcohol use (days): 0.86 SRD status offenses (incidents): −7.24 SRD Theft (incidents): −3.28 SRD crimes against persons (incidents): −2.69 DC ± MST Marijuana use (days): −30,17 Polydrug use (days): :-1.11 Alcohol use (days): 0.27 Heavy alcohol use (days): −0.45 SRD status offenses (incidents): −11.11 SRD Theft (incidents): −2.79 SRD crimes against persons (incidents): −3.90 DC ± MST ± CM Marijuana use (days): −27.86 Polydrug use (days): −6.76 Alcohol use (days): −7.56 Heavy alcohol use (days): −4.13 SRD status offenses (incidents): −10.38 SRD Theft (incidents): −3.19 SRD crimes against persons (incidents): −2.4 | Effects comparator (FC) Marijuana use (days): −15,43 Polydrug use (days): 2.27 Alcohol use (days): 2.97 Heavy alcohol use (days): 0.76 SRD status offenses (incidents): 9.22 SRD Theft (incidents): −5.54 SRD crimes against persons (incidents): 0.49 | Difference effects: The difference in effects were not showed in this study | ||||
Results | ACERS were calculated; average costs/ difference between mean incidents before and after treatment (negative means inefficient) | |||||
FC | DC | DC + MST | DC + MST + CM | |||
Marijuana use: Polydrug use: Alcohol use: Heavy alcohol use: SRD status offenses: SRD theft: SRD crimes against persons: | € 238 (215–262) € −1,619 (−8,8839–5,601) € −,1,239 (−6,546–5,601) € −4,857 (−10,632–918) € −400 (−1,206–398) € 663 (428–899) € −7,588 (−10,667–4,510) | € 545 (474–617) € −6,425 (−27,541–14,692) € −18,814 (−42,034–4,405) € −10,535 (−28,804–7,733) € 1,254 (1,132–1,376) € 2,773 (−2.441–7,987) € 3,377 (2,976–3,777) | € 410 (377–442) € 11,209 (−3,757–26,175) € −44,838 (−61,014–28,662) € 27,592 (−14,636–69,821) € 1,114 (907–1,321) € 4,428 (−1,224–10,081) € 3,175 (236–6,123) | € 461 (434–488) € 1,912 (1,624–2,182) € 1,699 (1,486–1,912) € 3,109 (1,708–4,511) € 1,239 (1,009–1,496) € 4,032 (1,204–6,859) € 5,346 (4,723–5,968) | ||
Studies considering costs and benefits of substance abuse | ||||||
Schoenwald (1996) [32] | Costs interventions (MST) Mental health outpatient (total): €4,242 Mental health day treatment (total): € 5,423 Mental health residential treatment (total): €6,899 Psychiatric inpatient (total): €15,752 Psychiatric emergency room (total): €1,150 Substance abuse outpatient (total): € 2,001 Substance abuse residential treatment (total): €3,450 Substance abuse inpatient (total): € 16,098 Marine Institute day treatment (total): € 18,926 Marine Institute residential treatment (total): € 3,036 Treatment costs: € 266,516 | Costs comparator (CAU) Mental health outpatient (total): € 19,075 Mental health day treatment (total): € 1,118 Mental health residential treatment (total): €0 Psychiatric inpatient (total): €18,513 Psychiatric emergency room (total): €3,450 Substance abuse outpatient (total): € 20,272 Substance abuse residential treatment (total): €43,695 Substance abuse inpatient (total): €93,771 Marine Institute day treatment (total): €28,618 Marine Institute residential treatment (total): €0 | Benefits interventions Incarceration days: €65,427 | Benefits CAU Incarceration days: €120,851 | ||
Results | MST: Total costs (costs + benefit) with incarceration = €408,919 and the total costs (costs + benefit) with incarceration per youth = €6,930 CAU: Total costs (costs + benefit) with incarceration = € 335,845 and the costs (costs + benefit) per youth = €5,693. Difference in total between groups = €1,019 | |||||
French (2003) [22] | Costs interventions (MET/CBT 5, MET/CBT 12, FSN, ACRA, MDFT) | Benefits interventions (MET/CBT 5, MET/CBT 12, FSN, ACRA, MDFT) | ||||
Treatment costs were measured | Health service utilization; Outpatient clinic/doctor’s office visit Days bothered by health/medical problem Substance-absue treatment utilization; Days in detoxification program; Day in inpatient treatment program; Day in long-term residential program; Intensive outpatient program visits; Regular outpatient program visits Education and employment; Days missed at school or training; Personal income; Days stressful for parents Day missed of work or school by parent Criminal activity; Arrests; Day on probation; Days on parole; Days in prison/jail; Days in juvenile detention | |||||
Incremental arm: MET/CBT5:€ 1,226 MET/CBT12: € 1,305 FSN: € 3,576 | Alternative arm: MET/CBT5: € 1,716 ACRA: € 1,551 MDFT: € 2,216 | Incremental arm: MET/CBT5 Baseline € 2,553 3 months: € 2,133 6 months: € 1,671 9 months: € 945 12 months: € 1,217 MET/CBT12 Baseline: € 2,179 3 months: € 2,433 6 months: € 828 9 months: € 1,431 12 months: € 687 FSN: Baseline: € 2,552 3 months: € 4,525 6 months: € 1,783 9 months: € 1,205 12 months: € 1,726 | Alternative arm: MET/CBT5 Baseline € 2,694 3 months: € 3,587 6 months: € 2,213 9 months: € 2,275 12 months: € 1,907 ACRA Baseline: € 2,506 3 months: € 3,691 6 months: € 1,748 9 months: € 3,113 12 months: € 3,237 MDFT: Baseline: € 2,019 3 months: € 3,938 6 months: € 1,467 9 months: € 2,573 12 months: € 2,098 | |||
Results | Net economic benefits (benefits + costs) relative to baseline: 3 different models were administred; Model 1: only time dummies for each of the follow-up periods (as treatment conditions were not included, we did not show the results. Model 2: time dummies and indicator variables for treatment condition. Model 3: time and treatment variables withan indicator variable for site. The last specification added numerous demographic and environmental controls. | |||||
MET/CBT12: Model 2: € −198 (349) Model 3: € −171 (346) Model 4: € −340 (334) FSN: Model 2: € 607* (343) Model 3: € 653 (340) Model 4: € 250 (333) *p < 0.1 | Acra: Model 2: € 369 (436) Model 3: € 530 (430) Model 4: € 554 (405) MDFT Model 2: −€ 61 (441) Model 3: € 128 (436) Model 4: € 100 (530) | |||||
McCollister (2009) [24] | Costs interventions (DC, DC/MST, DC) | Costs comparators (FC) | Benefits interventions (DC, DC/MST, DC) | Benefits comparators (FC) | ||
Treatment costs | Treatment costs | Criminal activity costs according to Self-reported criminal activity (SRD): DC: € 28.601 (94.314) DC/MST: €65.640 (240.559) DC/MST/CM: €80.222 (336.461) | Self-reported criminal activity (SRD): FC: € 206.045 (545.581) | |||
DC: €8,156 DC/MST: €11,547 DC/MST/CM: € 11,547 | FC: €3,304 | |||||
Results | After 12 months, total costs relative to FC with multivariate model (intervention costs not incorporated): DC: € -124,877 (−84,107) DC/MST: €-117,918 (−82,570) DC/MST/CM: €140,274 (/79.066)* All DC conditions generated reduction in crime costs, greater than average costs of treatment. |
Studies considering both costs and effects | |||||
---|---|---|---|---|---|
Sheidow (2004) [23] | Costs intervention (MST) Medicaid (government insurance program) costs (inpatient, Outpatient, Pharmacy, other costs), Other treatment costs paid for by study MST Medicaid costs: 0-end treatment (4 months): €9,311 (±7,755) Medicaid costs: End treatment-12 months: €13,237 (±15,144) Other treatment costs paid for by study: €11,617 | Costs comparator (CAU) Medicaid (government insurance program) costs (inpatient, Outpatient, Pharmacy, other costs), Other treatment costs paid for by study CAU Medicaid costs: 0-end treatment (4 months): €13,255 (±5,762) Medicaid costs: End treatment-12 months: €15,207 (±18,485) Other treatment costs paid for by study: €0 | Difference costs (CostsCAU-CostsMST) (after risk adjusted model): | ||
0-end treatment (total costs): End treatment- 12 months post-treatment (total costs): | -€ 1,828 -€452 (SE = 14) | ||||
Effects intervention CBCL: Externalizing scores, internalizing scores: GSI: Global severity index are measures The main effects were not showed in this study but only differences over time were presented. | Effects comparator CBCL: Externalizing scores, internalizing scores: GSI: Global severity index The main effects were not showed in this study but only differences over time were presented. | Difference effects (EffectsCAU-EffectsMST) (after risk adjusted model): | |||
0-end treatment: end treatment- 12 months post-treatment: | Externalizing:-14.75 (SE = 8.37) Internalizing:-14.19 (SE = 9.26) Global severity index: −0.03 (SE = 0.497) Externalizing:3.29 (SE = 9.97) Internalizing:-6.18 (SE = 9.67) Global severity index: −0.37 (SE = 0.428) | ||||
Results | ICER: 1 point improvement in externalizing scores for usual care was associated with a cost of €1,561. 1 point improvement in externalizing scores for MST was associated with a costs of €404. After 12 months both treatments have comparable costs and externalizing scores. | ||||
Studies considering costs and benefits | |||||
Olsson4 (2010) [26] | Costs intervention (MST) Treatment costs: € 10.789 Travel: € 53 (133) | Costs comparator (CAU) Travel: €151 (225) | Benefits intervention (MST) Psychosocial and behavioral effects: − Social services (placement): € 31.947 (€65.869) Social services (nonplacement): € 8.557 (19.459) National board of institutional care (rebate): € 3.009 (11.014) National board of institutional care (placements): € 3.593 (31.937) Wider societal costs and benefit: set to zero Psychosocial and behavioral effects: set to zero | Benefits comparator (CAU) Program effects Social services (Placement): € 36.707 (73.407) Social services (nonplacement): € 14.914 (15.405) National board of institutional care (rebate): € 2.375 (9.949) National board of institutional care (placements): 0 (0) SEK Wider societal costs and benefit: set to zero | |
Results | The net loss to society after two years is € 4.555 | ||||
Cary (2013) [28] | Costs interventions (MST + YOT) Treatment costs:€ 3.013 (1.940) Social worker: € 733 (446) Reparation worker: € 100 (131) Drugs worker: € 54 (74) Connexions worker: € 33 (69) Parenting worker: € 36 (137) Group worker: € 17 (34) Psychologist: € 17 (67) Other appointments:€ 20 (59) | Costs comparator (YOT) Social worker: € 1.023 (779) Reparation worker: € 83 (14) Drugs worker: € 78 (152) Connexions worker: € 18 (61) Parenting worker: € 90 (182) Group worker: € 22 (44) Psychologist: € 30 (91) Other appointments: € 26 (95) | Benefits interventions (MST + YOT) | Benefits comparator (YOT) | |
Offending behavior (Young offender information system): | |||||
€ 12,397 (18 472) | € 15,409 (24,013) | ||||
Results | Difference (Costs + benefits) between treatments € 1.612 (95 % C.I-€ 7.699-€ to 10.924) In the cost-effectiveness plane, we see, there is 63 % probability that the net benefit of MST + Yot is positive in favor of the MST + YOT group. | ||||
Dopp (2014) [30] | Costs interventions (MST) Costs per patient: € 9,756 | Costs comparator (CAU) Costs per patient: € 1,843 | Benefits intervention (MST) | Benefits comparator (IT) | |
Benefits for taxpayer Murder: € 0 Sexual offenses: € 922 Robbery: € 188 Assault: € 1.156 Property: € 2.395 Drug: € 916 Theft: € 131 Stolen property: € 24 Fraud: € 259 Assault: € 236 Drug: € 777 TOTAL: € 7.007 | Benefits for taxpayer Murder: € 0 Sexual offenses: € 602 Robbery: € 308 Assault: € 1.697 Property: € 1.899 Drug: € 1.334 Theft: € 188 Stolen property: € 53 Fraud: € 224 Assault: € 294 Drug: € 598 TOTAL: € 7.197 | ||||
Results | Crime victim avoided expenses Murder/manslaughter Tangible: € 6.125 Intangible: € 11.365 Sexual Tangible: € 259 Intangible: € 3.439 Robbery Tangible: € 575 Intangible: € 1.422 Assault Tangible: € 539 Intangible: € 2.926 Property Tangible: € 3.914 Intangible: € 0 Drug Tangible: € 0 Intangible: € 0 TOTAL Tangible: € 11.412 Intangible: € 19.151 | Net present values and benefit-cost ratios Net present value Referred youths Taxpayer: € 2.348 Crime victim tangible: € 2.389 Crime victim intangible € 9.375 Cumulative: € 29.939 Siblings: Taxpayer: € 674 Crime victim tangible: € 2.702 Crime victim intangible: € 4.533 Cumulative: € 6.561 Sibling pairs Taxpayer: € 1.399 Crime victim tangible: € 3.499 Crime victim intangible: € 11.238 Cumulative*: € 31.962 *: Includes the incremental costs of MST over IT Benefit cost ratio Referred youths Taxpayer: 1.3 Crime victim tangible: 1.3 Crime victim intangible 2.19 Cumulative: 4.78 Siblings: Taxpayer: - Crime victim tangible: - Crime victim intangible: - Cumulative: - Sibling pairs Taxpayer: 1.18 Crime victim tangible: 1.44 Crime victim intangible: 2.42 Cumulative*: 5.04 *: Includes the incremental costs of MST over CAU | Sensitivity analysis Max (plausible) values Crime victim intangible benefits: € 48.087 Sibling juvenile arrest rates: € 30.74 Discount rates: € 24.063 Min (plausible) values Crime victim intangible benefits: € 17.561 Sibling juvenile arrest rates:- Discount rates: € 36.704 | ||
Borduin (2015) [31] | Costs interventions (MST-PSB) Costs per patient: € 10,566 | Costs comparator (CAU) Costs per patient: €4,610 | Benefits intervention (MST-PSB) Benefits for taxpayer Murder: € 0 Sexual offenses: € 6.419 Robbery: € 2.189 Assault: € 0 Property: € 2.831 Drug: € 1.899 Theft: € 180 Stolen property€ 0 Fraud: € 91 Assault: € 250 Drug: € 512 TOTAL: € 14.371 | Benefits comparator (CAU) Benefits for taxpayer Murder: € 0 Sexual offenses: € 15.756 Robbery: € 0 Assault: € 2.194 Property: € 3.790 Drug: € 518 Theft: € 65 Stolen property: € 39 Fraud: € 75 Assault: € 289 Drug: € 112 TOTAL: € 22.839 | |
Crime victim avoided expenses Murder/manslaughter Tangible: € 41.048 Intangible: € 76.169 Sexual Tangible: € 1.739 Intangible: € 23.044 Robbery Tangible: € 3.850 Intangible: € 9.529 Assault Tangible: € 3.612 Intangible: € 19.611 Property Tangible: € 26.244 Intangible: € 0 TOTAL Tangible: € 76.494 Intangible: € 128.353 | Net present values and benefit-cost ratios Net present value Referred youths Taxpayer: € € 79.891 Crime victim tangible: € 70.538 Crime victim intangible € 122.397 Cumulative*: € 284.739 Siblings: Benefit cost ratio Referred youths Taxpayer: 14.41 Crime victim tangible: 12.84 Crime victim intangible 21.55 Cumulative: 48.81 *: Includes the incremental costs of MST over CAU | Sensitivity analysis Max (plausible) values Crime victim intangible benefits: € 387.085 Discount rates: € 239.009 Posttreatment arrest rates: € 478.277 Min (plausible) values Crime victim intangible benefits : € 188.217 Discount rates: € 311.107 Posttreatment arrest rates: € 91.673 |
Substance abuse
Delinquency/externalizing disorders
Quality of the studies
British Medical Journal Checklist | 1a
| 2a
| 3a
| 4a
| 5a
| 6a
| 7a
| 8a
| 9a
| 10a
| 11a
|
---|---|---|---|---|---|---|---|---|---|---|---|
1. The research question is stated. | - | - | ✓ | ✓ | ✓ | ✓ | ✓ | - | ✓ | ✓ | ✓ |
2. The economic importance of the research question is stated. | ✓ | - | ✓ | ✓ | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
3. The viewpoint(s) of the analysis are clearly stated and justified. | - | ✓ | - | ✓ | - | - | ✓ | ✓ | - | - | - |
4. The rationale for choosing alternative programmes or interventions compared is stated. | ✓ | - | - | - | - | - | ✓ | - | ✓ | - | - |
5. The alternatives being compared are clearly described | ✓ | ✓ | ✓ | ✓ | - | - | - | - | ✓ | ✓ | ✓ |
6. The form of economic evaluation used is stated. | - | ✓ | ✓ | ✓ | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
7. The choice of form of economic evaluation is justified in relation to the questions addressed. | NC | ✓ | ✓ | ✓ | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
8. The source(s) of effectiveness estimates used are stated. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
9. Details of the design and results of effectiveness study are given (if based on a single study). | ✓ | NA | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | - | ✓ | ✓ |
10. Details of the methods of synthesis or meta-analysis of estimates are given (if based on a synthesis of a number of effectiveness studies). | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
11. The primary outcome measure(s) for the economic evaluation are clearly stated. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
12. Methods to value benefits are stated. | ✓ | ✓ | NA | ✓ | ✓ | NA | ✓ | NA | ✓ | ✓ | ✓ |
13. Details of the subjects from whom valuations were obtained were given. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
14. Productivity changes (if included) are reported separately. | NA | ✓ | NA | NA | NA | NA | NA | NA | NA | - | - |
15. The relevance of productivity changes to the study question is discussed. | - | - | - | - | - | - | ✓ | - | - | - | - |
16. Quantities of resource use are reported separately from their unit costs. | ✓ | ✓ | - | - | - | - | - | - | ✓ | ✓ | ✓ |
17. Methods for the estimation of quantities and unit costs are described. | - | - | - | - | ✓ | - | ✓ | ✓ | ✓ | ✓ | ✓ |
18. Currency and price data are recorded. | ✓ | ✓ | - | ✓ | - | - | - | ✓ | ✓ | ✓ | ✓ |
19. Details of currency of price adjustments for inflation or currency conversion are given. | ✓ | ✓ | - | - | - | - | ✓ | - | ✓ | ✓ | ✓ |
20. Details of any model used are given | NA | ✓ | ✓ | ✓ | ✓ | ✓ | NA | NA | ✓ | NA | NA |
21. The choice of model used and the key parameters on which it is based are justified. | NA | - | - | ✓ | - | - | NA | NA | - | NA | NA |
22. Time horizon of costs and benefits is stated. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
23. The discount rate(s) is stated. | NA | NA | NA | NA | NA | NA | ✓ | NA | ✓ | ✓ | ✓ |
24. The choice of discount rate(s) is justified. | NA | NA | NA | NA | NA | NA | ✓ | NA | ✓ | ✓ | ✓ |
25. An explanation is given if costs and benefits are not discounted. | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
26. Details of statistical tests and confidence intervals are given for stochastic data. | - | - | ✓ | - | ✓ | - | ✓ | ✓ | ✓ | - | - |
27. The approach to sensitivity analysis is given. | ✓ | - | ✓ | - | - | - | ✓ | NC | ✓ | ✓ | ✓ |
28. The choice of variables for sensitivity analysis is justified. | ✓ | NA | NA | NA | NA | NA | ✓ | NA | ✓ | ✓ | ✓ |
29. The ranges over which the variables are varied are justified. | NC | NA | NA | NA | NA | NA | ✓ | NA | ✓ | ✓ | ✓ |
30. Relevant alternatives are compared. | ✓ | NC | - | NC | ✓ | NS | ✓ | ✓ | ✓ | ✓ | ✓ |
31. Incremental analysis is reported. | ✓ | ✓ | - | ✓ | ✓ | - | ✓ | - | ✓ | ✓ | ✓ |
32. Major outcomes are presented in a disaggregated as well as aggregated form | ✓ | ✓ | ✓ | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
33. The answer to the study question is given. | ✓ | NC | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
34. Conclusions follow from the data reported. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | - | - |
35. Conclusions are accompanied by the appropriate caveats. | - | - | ✓ | ✓ | - | ✓ | ✓ | ✓ | - | ✓ | - |
Total score British medical journal checklist | 68 % | 61 % | 63 % | 68 % | 54 % | 52 % | 86 % | 70 % | 83 % | 81 % | 77 % |
CHEC list | |||||||||||
1. Is the study population clearly described? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
2. Are competing alternatives clearly described? | ✓ | ✓ | ✓ | ✓ | - | - | - | - | ✓ | ✓ | ✓ |
3. Is a well-defined research question posed in answerable form? | - | - | ✓ | ✓ | ✓ | ✓ | ✓ | - | ✓ | ✓ | ✓ |
4. Is the economic study design appropriate to the stated objective? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
5. Is the chosen time horizon appropriate to include relevant costs and consequences? | NS | NS | ✓ | NS | NS | NS | ✓ | NS | NS | ✓ | ✓ |
6. Is the actual perspective chosen appropriate? | - | ✓ | - | - | - | - | ✓ | - | - | - | - |
7. Are all important and relevant costs for each alternative identified? | - | - | NS | - | - | - | - | - | - | ✓ | ✓ |
8. Are all costs measured appropriately in physical units? | ✓ | ✓ | - | - | - | - | ✓ | - | ✓ | ✓ | ✓ |
9. Are costs valued appropriately? | ✓ | ✓ | - | ✓ | ✓ | NS | ✓ | ✓ | ✓ | ✓ | ✓ |
10. Are all important and relevant outcomes for each alternative identified? | - | - | ✓ | ✓ | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
11. Are all outcomes measured appropriately? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
12. Are outcomes valued appropriately? | - | ✓ | ✓ | ✓ | ✓ | ✓ | - | ✓ | ✓ | ✓ | ✓ |
13. Is an incremental analysis of costs and outcomes of alternatives performed? | ✓ | ✓ | - | ✓ | ✓ | - | ✓ | - | ✓ | ✓ | ✓ |
14. Are all future costs and outcomes discounted appropriately? | NA | NA | NA | NA | NA | NA | ✓ | NA | ✓ | ✓ | ✓ |
15. Are all important variables, whose values are uncertain, appropriately subjected to sensitivity analysis? | ✓ | - | - | - | - | - | ✓ | - | ✓ | ✓ | ✓ |
16. Do the conclusions follow from the data reported? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | - | - |
17. Does the study discuss the generalizability of the results to other settings and patient/client groups? | - | - | ✓ | - | - | ✓ | ✓ | ✓ | - | - | - |
18. Does the article indicate that there is no potential conflict of interest of study researcher(s) and funder(s)? | - | ✓ | - | - | - | - | - | - | - | - | - |
19. Are ethical and distributional issues discussed appropriately? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Total score CHECb
| 56 % | 67 % | 61 % | 61 % | 50 % | 50 % | 79 % | 50 % | 79 % | 74 % | 74 % |
Risk of bias
Methodological summary
Treatment costs | Other healthcare costs | Costs outside health care sector | Perspective used in the economic evaluations | Clinical outcome measure | |
---|---|---|---|---|---|
(Schoenwald et al., 1996) [32] | ✓ | ✓ | Healthcare | - | |
(French et al., 2003) [22] | ✓ | Institution | - | ||
(Sheidow et al., 2004) [23] | ✓ | ✓ | Healthcare | CBCL/GSI | |
(Dennis et al., 2004) [29] | ✓ | Institution | - | ||
(McCollister et al., 2009) [24] | ✓ | Institution | SRD | ||
(French et al., 2008) [25] | ✓ | Institution | YSR/days of marijuana use | ||
(Olsson, 2010) [26] | ✓ | ✓ | Societal | - | |
(Sheidow et al., 2012) [27] | ✓ | Institution | TLFB/SRD | ||
(Cary et al., 2013) [28] | ✓ | Institution | - | ||
Dopp et al. (2014) [30] | ✓ | ✓ | Societal | - | |
Borduin et al. (2015) [31] | ✓ | ✓ | Societal | - |